Metraipolis › archive › dc_2dea3ce1bfbe

Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS — Europe PMC PMID:40844834

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40844834
DOI: 10.1093/ndt/gfaf166
License (as archived): solo-consultazione
Archived: 2026-11-07T03:57:31.806Z
SHA-256 of the archived text: bb8732a540e329ca67c77ee71af8b73288a0f6f7b994369407e3d47a271fadd2
Stable URL of this page: https://metraipolis.com/documento/dc_2dea3ce1bfbe

How to cite

Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS — Europe PMC PMID:40844834 — Europe PMC (en), https://europepmc.org/article/MED/40844834 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2dea3ce1bfbe (Metraipolis archive dc_2dea3ce1bfbe, sha256 bb8732a540e329ca67c77ee71af8b73288a0f6f7b994369407e3d47a271fadd2)

BibTeX

@misc{dc2dea3ce1bfbe,
  title = {Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS — Europe PMC PMID:40844834},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40844834},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2dea3ce1bfbe; sha256 bb8732a540e329ca67c77ee71af8b73288a0f6f7b994369407e3d47a271fadd2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40844834. Agents can read the archived copy with the MCP tool read_document.